SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-280620
Filing Date
2022-11-09
Accepted
2022-11-09 06:13:02
Documents
12
Period of Report
2022-11-08
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d353119d8k.htm   iXBRL 8-K 23104
  Complete submission text file 0001193125-22-280620.txt   143394

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA urgn-20221108.xsd EX-101.SCH 2848
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE urgn-20221108_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE urgn-20221108_pre.xml EX-101.PRE 11256
6 EXTRACTED XBRL INSTANCE DOCUMENT d353119d8k_htm.xml XML 3355
Mailing Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007
Business Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007 972 9 770 7601
UroGen Pharma Ltd. (Filer) CIK: 0001668243 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38079 | Film No.: 221370549
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences